These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37985979)

  • 21. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
    Dawe J; Wilkinson AL; Asselin J; Carter A; Pedrana A; Traeger MW; Thomas AJ; Curtis M; Cooper M; Howell J; Doyle JS; Hellard ME; Stoové M;
    Int J Drug Policy; 2022 Jun; 104():103696. PubMed ID: 35490624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
    O'Keefe D; Gunn J; Ryan K; Djordjevic F; Kerr P; Gold J; Elsum I; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana AE
    BMJ Open; 2022 Jan; 12(1):e057618. PubMed ID: 34983773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nurse-led, telehealth-driven hepatitis C management initiative in regional Victoria: Cascade of care from referral to cure.
    Rodrigues B; Parsons N; Haridy J; Bloom S; Day C; Haar G; Nicoll A; Sawhney R
    J Telemed Telecare; 2024 Apr; 30(3):497-504. PubMed ID: 34142898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
    Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploratory assessment: Nurse-led community health worker delivered HCV intervention for people experiencing homelessness.
    Nyamathi A; Salem BE; Lee D; Yu Z; Hudson A; Saab S; Shin SS; Jones-Patten A; Yadav K; Alikhani M; Clarke R; Chang A; White K; Gelberg L
    Public Health Nurs; 2023; 40(5):641-654. PubMed ID: 37132164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.
    Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N
    Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
    Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
    Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts.
    Robinson E; Byrne CJ; Carberry J; Radley A; Beer LJ; Inglis SK; Tait J; Macpherson I; Goldberg D; Hutchinson SJ; Hickman M; Dillon JF
    BMC Public Health; 2023 Jan; 23(1):54. PubMed ID: 36611156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
    Harney BL; Whitton B; Lim C; Paige E; McDonald B; Nolan S; Pemberton D; Hellard ME; Doyle JS
    Int J Drug Policy; 2019 Oct; 72():195-198. PubMed ID: 30981613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.